UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Precision oncology: origins, optimism, and potential

The lancet oncology, 2016-02, Vol.17 (2), p.e81-e86

2016

Volltextzugriff (PDF)

CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib

Seminars in oncology, 2017-12, Vol.44 (6), p.395-403

2017

Volltextzugriff (PDF)

Cancer Drugs in the United States: Justum Pretium—The Just Price

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3600-3604

2013

Volltextzugriff (PDF)

Precision Oncology: A Strategy we were not Ready to Deploy

Seminars in oncology, 2016-02, Vol.43 (1), p.9-12

2016

Volltextzugriff (PDF)

The High Cost of Ignorance in Oncology

Seminars in oncology, 2016-12, Vol.43 (6), p.623-624

2016

Volltextzugriff (PDF)

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Journal of clinical oncology, 2009-11, Vol.27 (32), p.5410-5417

2009

Volltextzugriff (PDF)

Pseudo-progressing to an unmet need

Seminars in oncology, 2017-02, Vol.44 (1), p.1-2

2017

Volltextzugriff (PDF)

Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4619-4629

2009

Volltextzugriff (PDF)

Seminars in oncology 50th anniversary

Seminars in oncology, 2024-02, Vol.51 (1-2), p.1-1

Fojo, Tito

2024

Volltextzugriff (PDF)

Moving a Pioneer Journal Into the Future

Seminars in oncology, 2016-02, Vol.43 (1), p.1-1

2016

Volltextzugriff (PDF)

MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors

Surgery, 2013-12, Vol.154 (6), p.1224-1229

2013

Volltextzugriff (PDF)

The flaws in assessing and reporting the toxicities of oral targeted therapies: Everolimus as an example

Seminars in oncology, 2023-02, Vol.50 (1-2), p.1-6

Fojo, Tito

2023

Volltextzugriff (PDF)

The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward

Seminars in oncology, 2022-12, Vol.49 (6), p.427-428

Fojo, Tito

2022

Volltextzugriff (PDF)

The flaws in assessing and reporting the toxicities of oral targeted therapies

Seminars in oncology, 2023-02, Vol.50 (1-2), p.1-6

Fojo, Tito

2023

Volltextzugriff (PDF)

New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia

Journal of clinical oncology, 2013-05, Vol.31 (13), p.1690-1698

2013

Volltextzugriff (PDF)

Metastatic Pheochromocytoma/Paraganglioma Related to Primary Tumor Development in Childhood or Adolescence: Significant Link to SDHB Mutations

Journal of clinical oncology, 2011-11, Vol.29 (31), p.4137-4142

2011

Volltextzugriff (PDF)

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis

The lancet oncology, 2017, Vol.18 (1), p.143-154

2017

Volltextzugriff (PDF)

Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example

PloS one, 2014-05, Vol.9 (5), p.e96316

2014

Volltextzugriff (PDF)

Desperation Oncology

Seminars in oncology, 2018-06, Vol.45 (3), p.105-106

Fojo, Tito

2018

Volltextzugriff (PDF)

Practical Considerations in the Evaluation and Management of Adrenocortical Cancer

Seminars in oncology, 2010-12, Vol.37 (6), p.619-626

2010

Volltextzugriff (PDF)

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Drug resistance updates, 2012-02, Vol.15 (1), p.50-61

2012

Volltextzugriff (PDF)

Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US

Journal of cancer policy, 2014-03, Vol.2 (1), p.1-11

2014

Volltextzugriff (PDF)

Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape

BMC medical genomics, 2020-11, Vol.13 (1), p.165-15, Article 165

2020

Volltextzugriff (PDF)

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

Cell reports (Cambridge), 2013-02, Vol.3 (2), p.277-281

2013

Volltextzugriff (PDF)

Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience

The Annals of thoracic surgery, 2011-10, Vol.92 (4), p.1195-1200

2011

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(107)

Publikationsform

Artikel
(115)

Sprache

Englisch
(115)

Erscheinungsjahr

n.n

Thema

Science & Technology
(88)
Life Sciences & Biomedicine
(86)
Humans
(75)
Oncology
(59)
Female
(33)
Male
(25)
Tumors
(23)
Biological And Medical Sciences
(22)
Medical Sciences
(21)
Cancer
(18)
Middle Aged
(18)
Adult
(17)
Antineoplastic Agents - Therapeutic Use
(13)
Neoplasms - Drug Therapy
(13)
Aged
(12)
Hematology, Oncology And Palliative Medicine
(12)
Drug Resistance
(11)
Pharmacology & Pharmacy
(11)
Patients
(10)
Treatment Outcome
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Precision oncology: origins, optimism, and potential

CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib

Cancer Drugs in the United States: Justum Pretium—The Just Price

Precision Oncology: A Strategy we were not Ready to Deploy

The High Cost of Ignorance in Oncology

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Pseudo-progressing to an unmet need

Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma

Seminars in oncology 50th anniversary

Moving a Pioneer Journal Into the Future

MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors

The flaws in assessing and reporting the toxicities of oral targeted therapies: Everolimus as an example

The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward

The flaws in assessing and reporting the toxicities of oral targeted therapies

New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia

Metastatic Pheochromocytoma/Paraganglioma Related to Primary Tumor Development in Childhood or Adolescence: Significant Link to SDHB Mutations

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis

Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example

Desperation Oncology

Practical Considerations in the Evaluation and Management of Adrenocortical Cancer

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US

Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience

Aktive Filter

Suchergebnisse filtern